FTSE MIB
33.565,51 -388,77 (-1,14%) Dow Jones
37.735,11 -248,13 (-0,65%) Nasdaq
15.885,02 -290,08 (-1,79%) Nikkei 225
38.471,20 -761,60 (-1,94%) Petrolio
85,07 -0,34 (-0,40%) Bitcoin EUR
59.332,38 -2.842,48 (-4,57%)
GSK plc (GSK)
Preborsa:
| Chiusura precedente | 40,66 |
| Aperto | 40,90 |
| Denaro | 40,14 x 2900 |
| Lettera | 40,07 x 1800 |
| Min-Max giorno | 40,44 - 41,06 |
| Intervallo di 52 settimane | 33,33 - 43,84 |
| Volume | |
| Media Volume | 3.633.132 |
| Capitalizzazione | 84,307B |
| Beta (5 anni mensile) | 0,27 |
| Rapporto PE (ttm) | 13,55 |
| EPS (ttm) | 2,99 |
| Prossima data utili | N/D |
| Rendimento e dividendo (futuro) | 1,47 (3,62%) |
| Data ex dividendo | 22 feb 2024 |
| Stima target 1A | 44,10 |
GlobeNewswireGlobal CAR T-cell Therapy Market Projected to Reach $83 Billion by 2032
PALM BEACH, Fla., Oct. 12, 2023 (GLOBE NEWSWIRE) -- FinancialNewsMedia.com News Commentary - Significant influences driving the CAR T-cell therapy market is a rising demand for model therapeutics for treatment of cancer, increase in prevalence of cancer and an escalating awareness of CAR T-cell therapy medicines. The CAR T-cell therapy market is currently going through a rapid expansion, owing to rapidly expanding clinical trial activities and recent commercialization of CAR-T cell therapy, whic
GlobeNewswireSpringWorks Therapeutics Announces Clinical Data Presentations of Nirogacestat in Combination with BCMA-Directed Therapies at the European Hematology Association 2023 Congress
STAMFORD, Conn., May 11, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, announced today that data from two collaborator-sponsored clinical studies evaluating nirogacestat, an investigational oral gamma secretase inhibitor, in combination with B-cell maturation agent (BCMA) therapies in patients with relapsed or refractory multiple my
GlobeNewswireSCYNEXIS Announces First Quarter 2023 Financial Results and Provides Corporate Update
SCYNEXIS announced an exclusive license agreement with GSK plc (LSE/NYSE: GSK) for the global rights to develop and commercialize BREXAFEMME® (ibrexafungerp tablets). SCYNEXIS will receive an upfront payment from GSK of $90 million upon deal close with future performance-based milestone payments of up to $503 million and tiered royalties.SCYNEXIS ended Q1 with cash, cash equivalents and short-term investments of $54.8 million, and upon receipt of the upfront payment from GSK will have a projecte
